Market
Biogen's stock performance relative to the biotech index by end of 2025
3
Chris Viehbacher•JPMorgan Healthcare Conference•San Francisco•Viehbacher•Biogen•Sage Therapeutics•Zurzuvae•Sage
Resolution / Starting Odds
Outperforms the biotech index • 25%
Performs in line with the biotech index • 25%
Underperforms the biotech index • 25%
Highly volatile with no clear trend • 25%
Stock market data from Nasdaq or other reputable financial data sources
Story
Biogen CEO Confirms Intent to Acquire Biotechs, Including $469 Million Offer for Sage Therapeutics
Jan 12, 2025, 04:01 PM
Biogen Inc. is actively seeking to expand its portfolio through acquisitions in the biotech sector, as confirmed by CEO Chris Viehbacher at the JPMorgan Healthcare Conference in San Francisco. Viehbacher expressed Biogen's intent to engage in deals, though he did not specify the size of these potential acquisitions. This comes after Biogen's recent $469 million offer to acquire Sage Therapeutics, its partner in marketing Zurzuvae, a pill for postpartum depression. The offer, which is less than Sage's current cash reserves, is unlikely to be accepted due to Sage's recent clinical failures and stock price decline. Biogen's strategy is to target biotechs with drugs in mid- and late-stage clinical development to augment its growth.
View original story
Similar markets
Stoke Therapeutics • 25%
Multiple companies • 25%
No further acquisitions • 25%
Another named biotech company • 25%
Remains stable (±10%) • 25%
Increases by more than 50% • 25%
Increases by 30-50% • 25%
Decreases by more than 10% • 25%
Underperform • 25%
Outperform slightly • 25%
Outperform significantly • 25%
Match performance • 25%
Decrease • 25%
No change • 25%
Increase by less than 10% • 25%
Increase by 10% or more • 25%
Acquisition not completed • 25%
Acquisition completed at a different price • 25%
Acquisition completed at proposed price • 25%
Acquisition rejected • 25%
Tesla outperforms all major competitors • 25%
Mixed performance • 25%
Tesla underperforms compared to major competitors • 25%
Tesla performs similarly to major competitors • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Outperform • 25%
Best performer • 25%
Worst performer • 25%
Third best performer • 25%
Second best performer • 25%